| Issue Date |
Title |
Author(s) |
| 2011 |
A 3-DAY ORAL APREPITANT REGIMEN PROVIDES SUPERIOR PREVENTION OF CINV OVER STANDARD THERAPY IN CHINESE PATIENTS RECEIVING HIGH-DOSE CISPLATIN |
Zhang, Li;Cheng, Ying;Zhang, Hong-Yu;Zhou, Caicun;Han, Baohui;Zhang, Yiping;Huang, Cheng;Chang, Jianhua;Song, Xiang Q.;Liang, Jun;Liang, Houjie;Bai, Chunxue;Yu, Shiying;Chen, Jia;Wang, Jie;Pan, Hongming;Carides, Alexandra;Chitkara, Denesh |
| 2018 |
Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study |
Li, Jin;Xu, Ruihua;Qin, Shukui;Liu, Tianshu;Pan, Hongming;Xu, Jianming;Bi, Feng;Lim, Robert;Zhang, Suzhan;Ba, Yi;Bai, Yuxian;Fan, Nanfeng;Tsuji, Akihito;Yeh, Kun-Huei;Ma, Brigette;Wei, Vivian;Shi, Dongmei;Magherini, Emmanuelle;Shen, Lin |
| 2019 |
Association between hand-foot skin reaction (HFSR) and survival benefit of fruquintinib in FRESCO trial. |
Li, Jin;Qin, Shukui;Bai, Yuxian;Deng, Yanhong;Yang, Lei;Xu, Ruihua;Chen, Zhendong;Zhong, Haijun;Pan, Hongming;Guo, Weijian;Shu, Yongqian;Yuan, Ying;Xu, Jianming;Shen, Lin;Wang, Ning;Zhu, Chao;Fan, Songhua;Gong, Wei;Wang, Wei |
| 2019 |
Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastases (version 2018) |
Xu, Jianmin;Fan, Jia;Qin, Xinyu;Cai, Jianqiang;Gu, Jin;Wang, Shan;Wang, Xishan;Zhang, Suzhan;Zhang, Zhongtao;Ba, Yi;Bu, Jianhong;Cai, Jianhui;Cai, Sanjun;Zeng, Shan;Zeng, Zhaochong;Chen, Gong;Chen, Yu;Chen, Zihua;Chen, Zongyou;Cheng, Jiemin;Chi, Pan;Dai, Guanghai;Dai, Yong;Deng, Yanhong;Ding, Kefeng;Fang, Xuedong;Fu, Chuangang;Gong, Jianping;Hao, Chunyi;He, Yulong;Huang, Zhongcheng;Ji, Jiafu;Jia, Baoqing;Jiang, Kewei;Jin, Jing;Kong, Dalu;Lan, Ping;Li, Dechuan;Li, Guoli;Li, Jin;Li, Leping;Li, Yunfeng;Li, Zhixia;Liang, Houjie;Liang, Xiaobo;Lin, Feng;Lin, Jianjiang;Liu, Hongjun;Liu, Tianshu;Liu, Yunpeng;Pan, Hongming;Pan, Zhizhong;Pei, Haiping;Peng, Tao;Ren, Li;Shen, Lin;Song, Chun;Song, Tianqiang;Su, Xiangqian;Sun, Yihong;Tao, Min;Tian, Liguo;Wan, Desen;Wang, Jianping;Wang, Guiying;Wang, Guiyu;Wang, Haijiang;Wang, Jianhua;Wang, Lei;Wang, Xin;Wang, Yajie;Wang, Yi;Wang, Ziqiang;Wei, Ye;Wei, Dong;Xia, Feng;Xia, Jianguo;Xia, Lijian;Xing, Baocai;Xiong, Bin;Xu, Jianming;Xu, Nong;Xu, Ruihua;Xu, Ye;Xu, Zekuan;Xu, Zhongfa;Yang, Shujun;Yao, Hongwei;Ye, Yingjiang;Yu, Peiwu;Yuan, Ying;Zhang, Jun;Zhang, Keliang;Zhang, Wei;Zhang, Xiaotian;Zhang, Yanqiao;Zhang, Youcheng;Zhang, Zhen;Zhao, Qingchuan;Zhao, Ren;Zheng, Shu;Zhou, Aiping;Zhou, Jian;Zhou, Zongguang |
| 2013 |
The Chinese subgroup from a randomized phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone as second-line treatment of HER2-amplified advanced gastric cancer (AGC) in Asian countries |
Sun, Guo-ping;Sun, Yan;Xu, Rui-hua;Xu, Jian-Ming;Li, Jin;Wang, Jin-Wan;Qin, Shukui;Feng, Ji Feng;Ba, Yi;Shen, Lin;Bai, Yu-Xian;Sun, Yihong;Pan, Hongming;Cheng, Ying;Yu, Shiying;Zhong, Haijun;Bai, Li;Luo, Rongcheng;Kobayashi, Mikiro;Ohtsu, Atsushi |
| May-2020 |
CSCO ablation expert workshop report: Recommendations for the management of tumor ablation during the coronavirus disease 2019 epidemic |
Shen, Yehua;Cheng, Chien-Shan;Wang, Peng;Zhu, Xu;Lei, Guangyan;Fang, Yong;Li, Hailiang;Fan, Weijun;Pan, Hongming;Tang, Zhe;Ma, Kuansheng;Li, Xiaoguang;Lin, Zhengyu;Zhuang, Yiping;Ye, Xin;Zhai, Bo;Han, Yue;Huang, Jinhua;Xu, Huixiong;Zheng, Rongqin;Chen, Rufu;Yu, Jie;Xu, Dong;Wang, Zhongmin;Meng, Zhiqiang |
| 20-May-2020 |
Early carcinoembryonic antigen (CEA) dynamics to predict fruquintinib efficacy in FRESCO, a 3+line metastatic colorectal carcinoma (mCRC) phase III trial. |
Bai, Yuxian;Qin, Shukui;Li, Jin;Deng, Yanhong;Yang, Lei;Xu, Rui-hua;Chen, Zhendong;Zhong, Haijun;Pan, Hongming;Guo, Weijian;Shu, Yongqian;Yuan, Ying;Xu, Jianming;Shen, Lin;Wang, Ning;Zhang, Bin;Zhang, Qiang;Fan, Songhua;Guo, Xiaojun;Peng, Mengye |
| 2018 |
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer The FRESCO Randomized Clinical Trial |
Li, Jin;Qin, Shukui;Xu, Rui-Hua;Shen, Lin;Xu, Jianming;Bai, Yuxian;Yang, Lei;Deng, Yanhong;Chen, Zhen-dong;Zhong, Haijun;Pan, Hongming;Guo, Weijian;Shu, Yongqian;Yuan, Ying;Zhou, Jianfeng;Xu, Nong;Liu, Tianshu;Ma, Dong;Wu, Changping;Cheng, Ying;Chen, Donghui;Li, Wei;Sun, Sanyuan;Yu, Zhuang;Cao, Peiguo;Chen, Haihui;Wang, Jiejun;Wang, Shubin;Wang, Hongbing;Fan, Songhua;Hua, Ye;Su, Weiguo |
| 2017 |
Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study |
Xu, Ruihua;Yu, Xianjun;Hao, Jihui;Wang, Liwei;Pan, Hongming;Han, Guohong;Xu, Jianming;Zhang, Yanqiao;Yang, Shujun;Chen, Jia;Ying, Jieer;Dai, Guanghai;Li, Mingyu;Begic, Damir;Lu, Brian;Shen, Lin |
| 2019 |
Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition) |
Li, Jian;Yuan, Ying;Yang, Fan;Wang, Yi;Zhu, Xu;Wang, Zhenghang;Zheng, Shu;Wan, Desen;He, Jie;Wang, Jianping;Ba, Yi;Bai, Chunmei;Bai, Li;Bai, Wei;Bi, Feng;Cai, Kaican;Cai, Muyan;Cai, Sanjun;Chen, Gong;Chen, Keneng;Chen, Lin;Chen, Pengju;Chi, Pan;Dai, Guanghai;Deng, Yanhong;Ding, Kefeng;Fan, Qingxia;Fang, Weijia;Fang, Xuedong;Feng, Fengyi;Fu, Chuangang;Fu, Qihan;Gu, Yanhong;He, Yulong;Jia, Baoqing;Jiang, Kewei;Lai, Maode;Lan, Ping;Li, Enxiao;Li, Dechuan;Li, Jin;Li, Leping;Li, Ming;Li, Shaolei;Li, Yexiong;Li, Yongheng;Li, Zhongwu;Liang, Xiaobo;Liang, Zhiyong;Lin, Feng;Lin, Guole;Liu, Hongjun;Liu, Jianzhong;Liu, Tianshu;Liu, Yunpeng;Pan, Hongming;Pan, Zhizhong;Pei, Haiping;Qiu, Meng;Qu, Xiujuan;Ren, Li;Shen, Zhanlong;Sheng, Weiqi;Song, Chun;Song, Lijie;Sun, Jianguo;Sun, Lingyu;Sun, Yingshi;Tang, Yuan;Tao, Min;Wang, Chang;Wang, Haijiang;Wang, Jun;Wang, Shubin;Wang, Xicheng;Wang, Xishan;Wang, Ziqiang;Wu, Aiwen;Wu, Nan;Xia, Lijian;Xiao, Yi;Xing, Baocai;Xiong, Bin;Xu, Jianmin;Xu, Jianming;Xu, Nong;Xu, Ruihua;Xu, Zhongfa;Yang, Yue;Yao, Hongwei;Ye, Yingjiang;Yu, Yonghua;Yu, Yueming;Yue, Jinbo;Zhang, Jingdong;Zhang, Jun;Zhang, Suzhan;Zhang, Wei;Zhang, Yanqiao;Zhang, Zhen;Zhang, Zhongtao;Zhao, Lin;Zhao, Ren;Zhou, Fuxiang;Zhou, Jian;Jin, Jing;Gu, Jin;Shen, Lin |
| Jul-2021 |
First-Line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis. |
Shen, Lin;Bai, Yuxian;Lin, Xiaoyan;Li, Wei;Wang, Jufeng;Zhang, Xiaochun;Pan, Hongming;Bai, Chunmei;Bai, Li;Cheng, Ying;Zhang, Jingdong;Zhong, Haijun;Ba, Yi;Hu, Wenwei;Xu, Ruihua;Guo, Weijian;Qin, Shukui;Yang, Nong;Lu, Jianwei;Shitara, Kohei;Lei, Ming;Li, Mingshun;Bao, Nicole;Chen, Tian;Liu, Tianshu |
| Oct-2022 |
First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis |
Liu, Tianshu;Bai, Yuxian;Lin, Xiaoyan;Li, Wei;Wang, Jufeng;Zhang, Xiaochun;Pan, Hongming;Bai, Chunmei;Bai, Li;Cheng, Ying;Zhang, Jingdong;Zhong, Haijun;Ba, Yi;Hu, Wenwei;Xu, Ruihua;Guo, Weijian;Qin, Shukui;Yang, Nong;Lu, Jianwei;Shitara, Kohei;Lei, Ming;Li, Mingshun;Bao, Nicole;Chen, Tian;Shen, Lin |
| 2013 |
The Impact of Nutritional Status, Nutritional Risk, and Nutritional Treatment on Clinical Outcome of 2248 Hospitalized Cancer Patients: A Multi-Center, Prospective Cohort Study in Chinese Teaching Hospitals |
Pan, Hongming;Cai, Sanjun;Ji, Jiafu;Jiang, Zhiwei;Liang, Houjie;Lin, Feng;Liu, Xiyong |
| Aug-2020 |
National guidelines for diagnosis and treatment of colorectal cancer 2020 in China (English version) |
Sun, Yan;Zheng, Shu;Wan, Desen;Gu, Jin;Wang, Jianping;Zhang, Suzhan;Cai, Sanjun;Fang, Xuedong;Fu, Chuangang;Jia, Baoqing;Kong, Dalu;Lan, Ping;Pan, Zhizhong;Pei, Haiping;Qiu, Huizhong;Song, Chun;Wang, Guiying;Wang, Xishan;Wang, Ziqiang;Xu, Jianmin;Xu, Zhongfa;Yan, Jin;Ye, Yingjiang;Yu, Yueming;Zhang, Zhongtao;Zhao, Ren;Lian, Lei;Liu, Qian;Peng, Yifan;Shen, Lin;Xu, Ruihua;Li, Jin;Ba, Yi;Bai, Chunmei;Bai, Li;Deng, Yanhong;Li, Jian;Liu, Tianshu;Liu, Yunpeng;Pan, Hongming;Tao, Min;Xu, Jianming;Yuan, Xianglin;Yuan, Ying;Zhang, Yanqiao;Zhou, Aiping;Wang, Feng;Wang, Xicheng;Li, Yexiong;Zhang, Zhen;Cai, Yong;Gao, Yuanhong;Jin, Jing;Li, Yongheng;Liu, Shixin;Wang, Renben;Wu, Junxin;Zhang, Hongyan;Zhu, Li;Zhu, Yuan;Tang, Yuan;Liang, Zhiyong;Jin, Mulan;Liang, Li;Qiu, Zhiqiang;Sheng, Weiqi;Sun, Baocun;Xue, Weicheng;Zhou, Weixun;Sun, Yingshi;Dong, Jiangning;Wang, Yi;Yu, Tao;Zhang, Xiaoyan;Zhou, Zhiyang;Sun, Ruijia;Wang, Juan;Sun, Ruijia;Tang, Yuan;Wang, Feng;Wang, Juan;Zhou, Weixun;Yang, Yong;Chen, Jiajia;Chen, Yongkang;Cheng, Yu;Han, Zihan;Huang, An;Huang, Dandan;Li, Xin;Li, Yukun;Shi, Jingyi;Shi, Mengyuan;Song, Can;Wang, Hanyang;Xu, Jingxuan |
| 2015 |
An open-label, randomized, multicenter, phase III study of S-1 and cisplatin versus docetaxel and cisplatin in patients with untreated advanced non-small-cell lung cancer. |
He, Jianxing;Shi, Yuankai;Chang, Jianhua;Wang, Mengzhao;Han, Baohui;Liu, Xiaoqing;Chen, Gongyan;Zhou, Caicun;Liu, Jiwei;Pan, Hongming;Huang, Cheng;Zhang, Shucai;Feng, Jifeng;Lin, Xiaoyan;Wang, Jie;Huang, Jianjin;Li, Fang;Qin, Shukui;Wang, Zhehai;Wang, Liwei |
| 2015 |
An open-label, randomized, multicenter, phase III study of S-1 and cisplatin versus docetaxel and cisplatin in patients with untreated advanced non-small-cell lung cancer. |
He, Jianxing;Shi, Yuankai;Chang, Jianhua;Wang, Mengzhao;Han, Baohui;Liu, Xiaoqing;Chen, Gongyan;Zhou, Caicun;Liu, Jiwei;Pan, Hongming;Huang, Cheng;Zhang, Shucai;Feng, Jifeng;Lin, Xiaoyan;Wang, Jie;Huang, Jianjin;Li, Fang;Qin, Shukui;Wang, Zhehai;Wang, Liwei |
| 2019 |
A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151) |
Si, Lu;Zhang, Xiaoshi;Shu, Yongqian;Pan, Hongming;Wu, Di;Liu, Jiwei;Lou, Fang;Mao, Lili;Wang, Xuan;Wen, Xizhi;Gu, Yanhong;Zhu, Lingjun;Lan, Shijie;Cai, Xin;Diede, Scott J.;Zhou, Yu;Ge, Zjun;Li, Jianfeng;Wu, Haiyan;Guo, Jun |
| Aug-2020 |
A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study |
Lu, Shun;Chen, Gongyan;Sun, Yuping;Sun, Sanyuan;Chang, Jianhua;Yao, Yu;Chen, Zhendong;Ye, Feng;Lu, Junguo;Shi, Jianhua;He, Jianxing;Liu, Xiaoqing;Zhang, Yiping;Liu, Zhihua;Fang, Jian;Cheng, Ying;Hu, Chunhong;Mao, Weidong;Hu, Yanping;Gong, Youling;Shan, Li;Yang, Zhixiong;Song, Yong;Li, Wei;Bai, Chong;Wang, Buhai;Ma, Rui;Zheng, Zhendong;Liu, Mingfang;Jie, Zhijun;Cao, Lejie;Liao, Wangjun;Pan, Hongming;Huang, Dongning;Chen, Yuan;Yang, Jinji;Qin, Shukui;Ma, Shenglin;Liang, Li;Liu, Zhe;Zhou, Jianying;Tao, Min;Huang, Yijiang;Qiu, Feng;Huang, Yunchao;Guan, Sha;Peng, Mengye;Su, Weiguo |
| Feb-2021 |
Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in FRESCO trial |
Qin, Shukui;Li, Jin;Bai, Yuxian;Deng, Yanhong;Yang, Lei;Xu, Rui-Hua;Zhong, Haijun;Chen, Zhendong;Pan, Hongming;Guo, Weijian;Shu, Yongqian;Xu, Jianming;Peng, Cike;Chen, Yun;Li, Hongyan;Wang, Ning;Guo, Xiaojun;Peng, Mengye;Fan, Songhua;Shen, Lin |
| 2018 |
Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer (mCRC) treated with fruquintinib in a phase II clinical trial. |
Li, Jin;Xu, Ruihua;Bai, Yuxian;Xu, Jianming;Liu, Tianshu;Shen, Lin;Wang, Liwei;Pan, Hongming;Han, Rubing;Chen, Yun;Peng, Cike;Fan, Songhua;Hua, Ye |
